AEON Biopharma (AEON) vs Biofrontera (BFRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biofrontera (BFRI) has outperformed AEON Biopharma (AEON) over the past year, losing 6.7% versus a loss of 66.3%. Biofrontera is the larger company by market cap ($14.4 million vs $13.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEON | BFRI |
|---|---|---|
| Share price | $0.276 | $0.97 |
| Market cap | $13.77M | $14.41M |
| 1-day change | -10.97% | +5.57% |
| YTD return | -71.82% | +70.18% |
| 1-year return | -66.30% | -6.73% |
| Forward P/E | — | 2.26 |
| EPS (TTM) | $-4.39 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.45 | $1.66 |
| 52-week low | $0.177 | $0.555 |
| Distance from 52-week high | -80.97% | -41.57% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +559.42% | +518.56% |
| Average volume | 8.59M | 547.45K |
| Shares outstanding | 49.88M | 14.85M |
| Employees | 8 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed AEON by 59.6 percentage points over the past year.
About AEON Biopharma
AEON stock →AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
AEON vs BFRI FAQ
Which is bigger, AEON Biopharma or Biofrontera?
Biofrontera (BFRI) is larger, with a market capitalization of $14.41M compared with $13.77M for AEON Biopharma (AEON).
Which stock has performed better over the past year, AEON or BFRI?
BFRI returned -6.73% over the past 12 months, compared with -66.30% for AEON (price return, excluding dividends). Past performance does not predict future results.
Are AEON Biopharma and Biofrontera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.